Document:

Exhibit 4.3

 

OMNIBUS APPROVAL AND AMENDMENT

 

WITH RESPECT TO:

 

·                                          SERIES F PREFERRED STOCK PURCHASE AGREEMENT;

 

·                                          FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT; AND

 

·                                          FIFTH AMENDED AND RESTATED VOTING AGREEMENT

 

This Omnibus Approval and Amendment (this “Amendment”) is entered into as of October     , 2014 (the “Effective Date”), by and among Invitae Corporation, a Delaware corporation (the “Company”), and the following parties:

 

·                  with respect to that certain Series F Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August 26, 2014, by and among the Company and the “Purchasers” party thereto, the undersigned holders of Series F Preferred Stock which, collectively, represent a Majority-In-Interest (as contemplated by Section 6.9 of the Purchase Agreement for purposes of determining the requisite approvals necessary to amend and/or waive terms of the Purchase Agreement);

 

·                  with respect to that certain Fifth Amended and Restated Investors’ Rights Agreement (the “Investors’ Rights Agreement”), dated as of August 26, 2014, by and among the Company and the “Investors” party thereto, the undersigned stockholders which, collectively, represent the holders of a majority of the outstanding Registrable Securities (with such capitalized terms having the meaning set forth in the Investor’s Rights Agreement and as contemplated by Section 6.6 of the Investor’s Rights Agreement for purposes of determining the requisite approvals necessary to amend and/or waive terms of the Investor’s Rights Agreement);

 

·                  with respect to that certain Fifth Amended and Restated Voting Agreement (the “Voting Agreement”), dated as of August 26, 2014, by and among the Company and the “Stockholders” party thereto, the undersigned stockholders which, collectively, represent the holders of a majority of the shares of Common Stock issued or issuable upon conversion of the shares of Preferred Stock held by the Investors (voting as a single class and on an as converted basis) (with such capitalized terms having the meaning set forth in the Voting Agreement and as contemplated by Section 5.8 of the Voting Agreement for purposes of determining the requisite approvals necessary to amend and/or waive terms of the Voting Agreement); and

 

·                  The entities identified as “Subsequent Purchasers” on Schedule A hereto, whereby each such Subsequent Purchaser is participating in the final Subsequent Closing of the sale and issuance of Series F Preferred Stock pursuant to the Purchase Agreement, as amended hereby (the “Final Closing”).

 

This Amendment is entered into with reference to the following facts:

 

 

A.                                    Capitalized terms that are used but are not otherwise defined herein shall have the meaning ascribed to such term in the Purchase Agreement.

 

B.                                    The Company and certain investors (including the Majority-In-Interest) are parties to the Purchase Agreement pursuant to which the Company has, prior to the Effective Date, issued and sold 24,500,000 shares of Series F Preferred Stock as part of the Initial Closing.

 

C.                                    The Company and certain stockholders of the Company are parties to: (i) the Investors’ Rights Agreement; (ii) Voting Agreement; and (iii) the Fifth Amended and Restated Right of First Refusal and Co-Sale Agreement (together with the Purchase Agreement, the Investors’ Rights Agreement and the Voting Agreement, the “Transaction Documents”).

 

D.                                    Prior to the issuance of shares of Series F Preferred Stock to the Subsequent Purchasers, the Restated Certificate is being amended and restated pursuant to an Amended and Restated Certificate of Incorporation in substantially the form attached hereto as Exhibit A (the “Amended and Restated Charter”) to, among other things: (i) increase the total number of shares of Common Stock authorized to be issued by 25,000,000 shares (i.e., from 135,131,524 shares to 160,131,524 shares); (ii) increase the total number of shares of Preferred Stock (as defined in the Restated Certificate) authorized to be issued by 25,000,000 shares (i.e., from 116,131,524 shares to 141,131,524 shares); and (iii) increase the total number of shares of Series F Preferred Stock authorized to be issued by 25,000,000 shares (i.e., from 35,000,000 shares to 60,000,000 shares).

 

E.                                     The parties hereto desire to: (i) provide for the issuance and sale pursuant to the Purchase Agreement as amended hereby of an additional 25,000,000 shares of Series F Preferred Stock for a total issuance and sale, pursuant to the Purchase Agreement, of 60,000,000 shares of Series F Preferred Stock (which is an increase beyond the maximum amount of up to 35,000,000 shares of Series F Preferred Stock originally contemplated by the Purchase Agreement); (ii) amend the Investors’ Rights Agreement and the Voting Agreement as provided herein in connection with issuance and sale of such additional shares of Series F Preferred Stock; (iii) confirm that the Subsequent Purchasers are parties to the Transaction Documents (as amended hereby) as purchasers of Series F Preferred Stock pursuant to the Purchase Agreement; (iv) amend and/or waive the terms and provisions of the Purchase Agreement (as well as any terms and provisions of the other Transaction Documents) to the extent necessary to provide for the issuance and sale of the Series F Preferred Stock contemplated hereby; and (v) confirm their consent and approval for all actions necessary or appropriate for the Company to provide for and implement the arrangements contemplated by the foregoing clauses (i), (ii), (iii) and (iv).

 

NOW, THEREFORE, the parties hereto agree as follows:

 

1.                                      Issuance as Part of Final Closing.  The issuance and sale to the Subsequent Purchasers as part of the Final Closing pursuant to the Purchase Agreement as amended hereby of 35,500,000 shares of Series F Preferred Stock for a total issuance and sale, pursuant to the Purchase Agreement, of 60,000,000 shares of Series F Preferred Stock (which is an increase beyond the maximum amount of up to 35,000,000 shares of Series F Preferred Stock originally contemplated by the Purchase Agreement) is hereby ratified, confirmed and approved.

 

2

 

2.                                      Parties to Transaction Documents; Signature Pages; Representations and Warranties.

 

(a)                                 The Subsequent Purchasers are intended for all purposes to be parties to the Transaction Documents as amended hereby as purchasers of Series F Preferred Stock pursuant to the Purchase Agreement (and as contemplated, respectively, by each of the other Transaction Documents).

 

(b)                                 Upon delivery of executed signature pages to each of the Transaction Documents, each of the Subsequent Purchasers shall be considered a “Purchaser” as such term is defined in and under the Purchase Agreement and an “Investor” as such term is defined in and under the other Transaction Documents; accordingly, each of the Subsequent Purchasers shall be entitled to the applicable rights and privileges, and be bound by the applicable obligations, all as set forth in each of the respective Transaction Documents as amended hereby.

 

(c)                                  The Company hereby represents and warrants to the Subsequent Purchasers that, except as set forth on the Disclosure Schedule as well as any supplement to the Disclosure Schedule delivered to the Subsequent Purchasers pursuant to Section 3(c) hereof, which exceptions shall be deemed to be part of the representations and warranties made hereunder, the representations and warranties of the Company contained in Sections 2.1 through 2.30 of the Purchase Agreement are true and complete as of the date of the Final Closing (except those representations and warranties which address matters only as of a particular date, which shall have been true and correct in all respects only as of such particular date).

 

3.                                      Conditions to Subsequent Purchaser’s Obligations at Final Closing.  The obligations of each Subsequent Purchaser to purchase the Shares at the Final Closing are subject to the fulfillment, on or before the Final Closing, of each of the following conditions, unless otherwise waived:

 

(a)                                 Representations and Warranties. The representations and warranties of the Company contained in Sections 2.1 through 2.30 of the Purchase Agreement shall be true and correct in all respects as of the Final Closing (except those representations and warranties which address matters only as of a particular date, which shall have been true and correct in all respects only as of such particular date), in each case as qualified by the information contained in the Disclosure Schedule as well as any supplement to the Disclosure Schedule delivered to the Subsequent Purchasers pursuant to Section 3(c) hereof.

 

(b)                                 Amended and Restated Charter.  The Company shall have filed the Amended and Restated Charter with the Secretary of State of the State of Delaware.

 

(c)                                  Officer’s Certificate.  The Chief Executive Officer of the Company shall deliver to the Subsequent Purchasers a certificate certifying that the representations and warranties of the Company contained in Section 2 of the Purchase Agreement are true and correct in all respects as of the Final Closing (except those representations and warranties which address matters only as of a particular date, which shall have been true and correct in all respects only as of such particular date), in each case as qualified by the information contained in the Disclosure

 

3

 

Schedule as well as any supplement to the Disclosure Schedule that accompanies such certificate.

 

(d)                                 Secretary’s Certificate. The Secretary of the Company shall have delivered to Subsequent Purchasers at the Final Closing a certificate certifying (i) the Bylaws of the Company, (ii) resolutions of the Board of the Company approving the transactions contemplated by this Amendment, and (iii) resolutions of the stockholders of the Company approving the Amended and Restated Charter.

 

(e)                                  Opinion of Company Counsel.  Such Subsequent Purchaser shall have received from Pillsbury Winthrop Shaw Pittman LLP, counsel for the Company, an opinion, dated as of the Final Closing, in substantially the form of Exhibit G attached to the Purchase Agreement, updated to account for the issuance of Series F Preferred Stock that took place at the Initial Closing.

 

(f)                                   Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Final Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to Subsequent Purchasers, and the Subsequent Purchasers (or their counsel) shall have received all such counterpart original and certified or other copies of such documents as reasonably requested. Such documents may include good standing certificates.

 

4.              Amendments to Investor’s Rights Agreement.

 

(a)                                 Effective upon the Final Closing, Section 2.1(a) of the Investors’ Rights Agreement is hereby amended and restated as follows:

 

“(a)                           Form S-1 Demand.  If at any time after the earlier of (i) eighteen (18) months after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of twenty percent (20%) of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to the Registrable Securities then outstanding if the anticipated aggregate offering price, net of Selling Expenses, is not less than $5 million, then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1 (c) and (d) and Section 2.3.”

 

(b)                                 Effective upon the Final Closing, Section 2.13 of the Investors’ Rights Agreement is hereby amended and restated as follows:

 

4

 

“2.13                  Termination of Registration Rights.  The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to occur of:

 

(a)                                 the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, and distribution of proceeds to or escrow for the benefit of the Holders in accordance with the Company’s Certificate of Incorporation in effect immediately prior to such transaction; and

 

(b)                                 the seventh anniversary of the IPO.”

 

(c)                                  Effective upon the Final Closing, clause (iii) of Section 3.3 of the Investors’ Rights Agreement are hereby amended and restated as follows:

 

“(iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, pursuant to which the Investors receive only cash and/or marketable securities, and distribution of proceeds to or escrow for the benefit of the Holders in accordance with the Company’s Certificate of Incorporation in effect immediately prior to such transaction.”

 

(d)                                 Effective upon the Final Closing, a new Section 3.5(d) is added to the Investors’ Rights Agreement as follows:

 

“(d)                           As long as BlackRock, Inc., together with its affiliates (collectively, “BlackRock”), holds at least fifty percent (50%) of the shares of Series F Preferred Stock purchased by BlackRock from the Company, the Company shall invite a representative of BlackRock to attend all meetings of the Board and its audit committee in a non-voting capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided that the Company reserves the right to exclude such representative from access to any of such materials or meetings or portions thereof if and to the extent that (i) in the good faith judgment of a majority of the directors of the Company after obtaining the advice of counsel such exclusion is reasonably necessary to preserve the attorney-client privilege, (ii) in the good faith judgment of a majority of the directors of the Company, such access would materially impair the due consideration by the Board of any matter, or (iii) any third party has, with respect to materials or information to be distributed to or considered by the Board, requested or required that such information not be shared beyond a group which does not include such representative.  BlackRock, Inc. shall cause such representative to hold in confidence all information provided under this Section 3.5(d) to the same extent an Investor is required to keep information obtained by it hereunder confidential pursuant to the provisions of Section 3.4.  Upon request, the Company shall exercise commercially reasonable efforts to provide BlackRock’s designated representative with the ability to attend meetings of the Board and its audit committee by telephone.”

 

5

 

(e)                                  Effective upon the Final Closing, Section 4.1(d) of the Investors’ Rights Agreement is hereby amended and restated as follows:

 

“(d)                           The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation), except that for purposes of this Section 4.1(d), Exempted Securities shall not include securities that are otherwise excluded from the anti-dilution provisions of the Company’s Certificate of Incorporation by consent of the requisite holders of Preferred Stock pursuant to Section 4.4.1(d)(xi) of Part B of Article Fourth of the Company’s Certificate of Incorporation as in effect on the date hereof and thus considered Exempted Securities under the Company’s Certificate of Incorporation; and (ii) shares of Common Stock issued in the IPO.”

 

(f)                                   Effective upon the Final Closing, clause (iii) of Section 4.2 of the Investors’ Rights Agreement is hereby amended and restated as follows:

 

“(iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, and distribution of proceeds to or escrow for the benefit of the Holders in accordance with the Company’s Certificate of Incorporation in effect immediately prior to such transaction, whichever event occurs first.”

 

(g)                                  Effective upon the Final Closing, clause (iii) of Section 5.6 of the Investors’ Rights Agreement is hereby amended and restated as follows:

 

“(iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, and distribution of proceeds to or escrow for the benefit of the Holders in accordance with the Company’s Certificate of Incorporation in effect immediately prior to such transaction, whichever event occurs first.”

 

5.              Amendments to Voting Agreement.

 

(a)                                 Effective upon the Final Closing, clause (iv) of Section 2.3(e) of the Voting Agreement is hereby amended and restated as follows:

 

“(iv) the aggregate consideration receivable by all holders of the Preferred Stock and Common Stock shall be allocated among the holders of Preferred Stock and Common Stock on the basis of the relative liquidation preferences to which the holders of each respective series of Preferred Stock and the holders of Common Stock are entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a Deemed Liquidation Event) in accordance with the Company’s Certificate of Incorporation in effect immediately prior to the Proposed Sale; and”

 

(b)                                 Effective upon the Final Closing, a new Section 2.3(g) is added to the Voting Agreement as follows (and the “; and” following Section 2.3(e) is moved to replace the period at the end of Section 2.3(f)):

 

6

 

“(g) no Investor shall be bound by any restrictive covenant in connection with a Sale of the Company that restricts its ability to conduct its business (such as a covenant not to compete) or places any similar business limitation on such Investor unless such Investor expressly agrees to such restrictive covenant in its discretion.”

 

(c)                                  Effective upon the Final Closing, new clauses (x), (xi) and (xii) are added to Section 5.8 of the Voting Agreement as follows (and the “; and” following clause (viii) as well as the “.” following clause (ix) of such Section 5.8 are replaced with “;”):

 

“(x)                           Section 2 of this Agreement shall not be amended or waived in a manner that is adverse to the holders of any series of the Preferred Stock but shall not similarly affect all of the holders of Preferred Stock without the written consent of the holders of a majority of the outstanding shares of such adversely affected series of Preferred Stock (voting or consenting exclusively, as a separate class), and this clause (x) shall not be amended or waived without the written consent of the holders of a majority of the outstanding shares of each series of the Preferred Stock (voting or consenting exclusively, as separate classes);

 

(xi)                              Section 2.3(g) of this Agreement and this clause (xi) shall not be amended or waived without the written consent of the holders of a majority of the outstanding shares of each series of the Preferred Stock (voting or consenting exclusively, as separate classes); and

 

(xii) Clause (iv) of Section 2.3(e) of this Agreement shall not be amended or waived if such amendment or waiver would result in or permit (at the time of such amendment or in the future) distribution of the aggregate consideration receivable by holders of a series of Preferred Stock other than in accordance with the liquidation preference to which the holders of such series of Preferred Stock would be entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a Deemed Liquidation Event) in accordance with the Company’s Certificate of Incorporation in effect immediately prior to a Proposed Sale without the written consent of the holders of a majority of the outstanding shares of such series of Preferred Stock (voting or consenting exclusively, as separate classes) and this clause (xii) shall not be amended or waived without the written consent of the holders of a majority of the outstanding shares of each series of the Preferred Stock (each voting or consenting exclusively, as separate classes).”

 

6.                                      Amendment/Waiver.  Without limiting the specific amendments set forth herein, the terms and provisions of the Transaction Documents are hereby amended and/or waived to the extent necessary to provide for the transactions and arrangements contemplated hereby.

 

7.                                      Confirmation.  Each party hereto hereby confirms its consent and approval for all actions necessary or appropriate for the Company to provide for and implement the arrangements contemplated by this Amendment.

 

8.                                      Inconsistency.  To the extent that any provision of any of the Transaction Documents is inconsistent with any of the transactions and arrangements contemplated by this Amendment, each and every such inconsistency, and any and all related breaches or defaults, are hereby waived, and any and all claims as a result thereof are hereby released, by the Company, each of the undersigned stockholders of the Company and each of the Subsequent Purchasers.

 

7

 

9.                                      Full Force and Effect.  The Transaction Documents, as amended and/or waived hereby, remain in full force and effect.

 

10.                               Counterparts; Fax.  This Amendment may be (i) executed in multiple counterparts, each of which shall be deemed an original and together shall constitute one document, and (ii) executed and delivered by facsimile (and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other parties).

 

[SIGNATURE PAGES FOLLOW]

 

8

 

IN WITNESS WHEREOF, the parties have executed this Omnibus Approval and Amendment as of the Effective Date.

 

COMPANY:

 

INVITAE CORPORATION

 

 

	
By:
    	
/s/ Randal W. Scott
    	
 
    
	
Name:
    	
Randal W. Scott
    	
 
    
	
Title:
    	
Chief Executive Officer
    	
 
    
	
 
    	
 
    
	
Address:
    	
 
    
	
458 Brannan Street
    	
 
    
	
San Francisco, CA 94107
    	
 
    
	
Facsimile: (415)520-9486
    	
 
    
	
E-mail: randy.scott@invitae.com
    	
 
    

 

9

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
BLACKROCK GLOBAL ALLOCATION FUND, INC.
    
	
 
    	
 
    
	
 
    	
By:
    	
BlackRock Investment Management, LLC
    
	
 
    	
Its:
    	
Investment Sub-Adviser
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ David Clayton
    
	
 
    	
Name:
    	
David Clayton
    
	
 
    	
Title:
    	
Authorized Signatory
    
				

 

Note:      Below information is only relevant for Purchasers in Final Closing

 

	
14,195,190
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
$28,390,380
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    
				

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
BLACKROCK GLOBAL ALLOCATION FUND, V.I. FUND OF   BLACKROCK VARIABLE SERIES FUNDS, INC.
    
	
 
    	
 
    
	
 
    	
By:
    	
BlackRock Investment Management, LLC
    
	
 
    	
Its:
    	
Investment Sub-Adviser
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ David Clayton
    
	
 
    	
Name:
    	
David Clayton
    
	
 
    	
Title:
    	
Authorized Signatory
    
				

 

Note:      Below information is only relevant for Purchasers in Final Closing

 

	
2,896,633
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
$5,793,266
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    
				

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

	
 
    	
BLACKROCK GLOBAL ALLOCATION PORTFOLIO OF BLACKROCK   SERIES FUND, INC.
    
	
 
    	
 
    
	
 
    	
By:
    	
BlackRock Investment Management, LLC
    
	
 
    	
Its:
    	
Investment Sub-Adviser
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ David Clayton
    
	
 
    	
Name:
    	
David Clayton
    
	
 
    	
Title:
    	
Authorized Signatory
    
				

 

Note:      Below information is only relevant for Purchasers in Final Closing

 

	
64,815
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
$129,630
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    
				

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

	
 
    	
BLACKROCK GLOBAL ALLOCATION FUND (AUSTRALIA)
    
	
 
    	
 
    
	
 
    	
By:
    	
BlackRock Investment Management, LLC
    
	
 
    	
Its:
    	
Investment Manager for BlackRock Investment Management (Australia)   Limited, the Responsible Entity of BlackRock Global Allocation Fund   (Australia)
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ David Clayton
    
	
 
    	
Name:
    	
David Clayton
    
	
 
    	
Title:
    	
Authorized Signatory
    
				

 

Note:      Below information is only relevant for Purchasers in Final Closing

 

	
247,498
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
$494,996
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    
				

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
MASSMUTUAL SELECT BLACKROCK GLOBAL ALLOCATION FUND
    
	
 
    	
 
    
	
 
    	
By:
    	
BlackRock Investment Management, LLC
    
	
 
    	
Its:
    	
Investment Sub-Adviser
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ David Clayton
    
	
 
    	
Name:
    	
David Clayton
    
	
 
    	
Title:
    	
Authorized Signatory
    
				

 

Note:      Below information is only relevant for Purchasers in Final Closing

 

	
167,841
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
$335,682
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    
				

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
JNL/BLACKROCK GLOBAL ALLOCATION FUND OF JNL SERIES   TRUST
    
	
 
    	
 
    
	
 
    	
By:
    	
BlackRock Investment Management, LLC
    
	
 
    	
Its:
    	
Investment Sub-Adviser
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ David Clayton
    
	
 
    	
Name:
    	
David Clayton
    
	
 
    	
Title:
    	
Authorized Signatory
    
				

 

Note:      Below information is only relevant for Purchasers in Final Closing

 

	
839,273
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
$1,678,546
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    
				

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
BLACKROCK GLOBAL FUNDS — GLOBAL ALLOCATION FUND
    
	
 
    	
 
    
	
 
    	
By:
    	
BlackRock Investment Management, LLC
    
	
 
    	
Its:
    	
Investment Sub-Adviser
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ David Clayton
    
	
 
    	
Name:
    	
David Clayton
    
	
 
    	
Title:
    	
Authorized Signatory
    
				

 

Note:      Below information is only relevant for Purchasers in Final Closing

 

	
5,603,429
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
$11,206,858
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    
				

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment. 

 

 

	
 
    	
BLACKROCK GLOBAL FUNDS — GLOBAL DYNAMIC EQUITY FUND
    
	
 
    	
 
    
	
 
    	
By:
    	
BlackRock Investment Management, LLC
    
	
 
    	
Its:
    	
Investment Sub-Adviser
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ David Clayton
    
	
 
    	
Name:
    	
David Clayton
    
	
 
    	
Title:
    	
Authorized Signatory
    
				

 

Note:      Below information is only relevant for Purchasers in Final Closing

 

	
369,458
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
$738,916
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    
				

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
AZL BLACKROCK GLOBAL ALLOCATION FUND, A SERIES OF   ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST
    
	
 
    	
 
    
	
 
    	
By:
    	
BlackRock Investment Management, LLC
    
	
 
    	
Its:
    	
Investment Sub-Adviser
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ David Clayton
    
	
 
    	
Name:
    	
David Clayton
    
	
 
    	
Title:
    	
Authorized Signatory
    
				

 

Note:      Below information is only relevant for Purchasers in Final Closing

 

	
186,439
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
$372,878
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    
				

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
667, L.P. (account #1)
    
	
 
    	
 
    
	
 
    	
By:
    	
BAKER BROS. ADVISORS LP,
    
	
 
    	
 
    	
management company and investment adviser to 667, L.P., pursuant to authority granted   to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not   as the general partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Scott Lessing
    
	
 
    	
 
    	
Scott Lessing, President
    

 

Note:  Below information is only relevant for Purchasers in Final Closing

 

	
629,600
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
$1,259,200.00
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
667, L.P. (account #2)
    
	
 
    	
 
    
	
 
    	
By:
    	
BAKER BROS. ADVISORS LP, 
    
	
 
    	
 
    	
management company and investment adviser to 667, L.P., pursuant to authority granted   to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not   as the general partner
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Scott Lessing
    
	
 
    	
 
    	
Scott Lessing, President
    

 

Note:  Below information is only relevant for Purchasers in Final Closing

 

	
447,230
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
$894,460
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
BAKER BROTHERS LIFE SCIENCES, L.P.
    
	
 
    	
 
    
	
 
    	
By:
    	
BAKER BROS. ADVISORS LP,
    
	
 
    	
 
    	
management company and investment adviser to Baker Brothers Life Sciences, L.P.,   pursuant to authority granted to it by Baker Brothers Life Sciences Capital,   L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the   general partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Scott Lessing
    
	
 
    	
 
    	
Scott Lessing, President
    

 

Note:  Below information is only relevant for Purchasers in Final Closing

 

	
8,923,170
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
$17,846,340
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
14159, L.P.
    
	
 
    	
 
    
	
 
    	
By:
    	
BAKER BROS. ADVISORS LP,
    
	
 
    	
 
    	
management company and investment adviser to 14159, L.P., pursuant to authority   granted to it by 14159 Capital, L.P., general partner to 14159, and not as   the general partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Scott Lessing
    
	
 
    	
 
    	
Scott Lessing, President
    

 

Note:  Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
GENESYS VENTURES II LP
    
	
 
    	
 
    
	
 
    	
By its general partner, Genesys General Partner LP
    
	
 
    	
 
    
	
 
    	
By its general partner, Genesys General Partner Inc.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Kelly Holman
    
	
 
    	
Name:
    	
Kelly Holman
    
	
 
    	
Title:
    	
A/S
    

 

Note:  Below information is only relevant for Purchasers in Final Closing

 

	
500,000
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
$1,000,000
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
CASDIN PARTNERS MASTER FUND, LP
    
	
 
    	
 
    
	
 
    	
By:
    	
Casdin Partners, GP, LLC
    
	
 
    	
Its:
    	
Manager
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Eli Casdin
    
	
 
    	
Name:
    	
Eli Casdin
    
	
 
    	
Its:
    	
Managing Member
    

 

Note:  Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
/s/ Randal W. Scott
    
	
 
    	
Randal W. Scott
    

 

Note:  Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
GENOMIC HEALTH, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Brad Cole
    
	
 
    	
Name:
    	
Brad Cole
    
	
 
    	
Title:
    	
COO & CFO
    

 

Note:  Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
BROE HOLDINGS, LLC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Pat Broe
    
	
 
    	
 
    	
Pat Broe
    
	
 
    	
 
    	
Manager
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
ORBIMED PRIVATE INVESTMENTS V, L.P.
    
	
 
    	
 
    
	
 
    	
By:
    	
OrbiMed Capital GP V LLC
    
	
 
    	
Its:
    	
General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
OrbiMed Advisors LLC
    
	
 
    	
Its:
    	
Managing Member
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Carl Gordon
    
	
 
    	
Name:
    	
Carl Gordon
    
	
 
    	
Title:
    	
Member
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
PERCEPTIVE LIFE SCIENCES MASTER
    
	
 
    	
FUND, LTD.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ James Mannix 
    
	
 
    	
 
    	
James Mannix 
    
	
 
    	
Title: 
    	
C.O.O
    
				

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
REDMILE PRIVATE INVESTMENTS I, LP
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Jeremy Green
    
	
 
    	
 
    	
Jeremy Green
    
	
 
    	
 
    	
Managing Member of the GP and/or
    
	
 
    	
 
    	
Management Company
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
REDMILE PRIVATE INVESTMENTS I
    
	
 
    	
AFFILIATES, LP
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Jeremy Green
    
	
 
    	
 
    	
Jeremy Green
    
	
 
    	
 
    	
Managing Member of the GP and/or
    
	
 
    	
 
    	
Management Company
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
REDMILE CAPITAL FUND, LP
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Jeremy Green
    
	
 
    	
 
    	
Jeremy Green
    
	
 
    	
 
    	
Managing Member of the Investment
    
	
 
    	
 
    	
Manager
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
REDMILE CAPITAL OFFSHORE FUND, LTD.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Jeremy Green
    
	
 
    	
 
    	
Jeremy Green
    
	
 
    	
 
    	
Managing Member of the Investment
    
	
 
    	
 
    	
Manager
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
REDMILE CAPITAL OFFSHORE FUND II, LTD.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Jeremy Green
    
	
 
    	
 
    	
Jeremy Green
    
	
 
    	
 
    	
Managing Member of the Investment
    
	
 
    	
 
    	
Manager
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
REDMILE SPECIAL OPPORTUNITIES FUND, LTD.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Jeremy Green
    
	
 
    	
 
    	
Jeremy Green
    
	
 
    	
 
    	
Managing Member of the Investment
    
	
 
    	
 
    	
Manager
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7th, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
ROCK SPRINGS CAPITAL MASTER FUND LP
    
	
 
    	
 
    
	
 
    	
By: 
    	
Rock Springs GP LLC
    
	
 
    	
Its: 
    	
General Partner
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Graham Mcphail
    
	
 
    	
Name: 
    	
Graham Mcphail
    
	
 
    	
Title: 
    	
Managing Director / Member
    
				

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
TITAN PERC LTD.
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Darren Ross
    
	
 
    	
 
    	
Darren Ross
    
	
 
    	
Title: 
    	
Director
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
THOMAS, McNERNEY & PARTNERS II, L.P.
    
	
 
    	
 
    
	
 
    	
By: 
    	
Thomas, McNerney & Partners II, LLC
    
	
 
    	
Its: 
    	
General Partner
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ Eric Aguiar
    
	
 
    	
 
    	
Eric Aguiar
    
	
 
    	
 
    	
Manager
    
				

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
TMP NOMINEE II, LLC
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Eric Aguiar
    
	
 
    	
 
    	
Eric Aguiar
    
	
 
    	
 
    	
Manager
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 9, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
TMP ASSOCIATES II, L.P.
    
	
 
    	
 
    
	
 
    	
By:
    	
Thomas, McNerney & Partners II, LLC
    
	
 
    	
Its:
    	
General Partner
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Eric Aguiar
    
	
 
    	
 
    	
Eric Aguiar
    
	
 
    	
 
    	
Manager
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
HAWKES BAY MASTER INVESTORS (CAYMAN) LP
    
	
 
    	
 
    
	
 
    	
By:
    	
Wellington Management Company, LLP,
    
	
 
    	
 
    	
as investment adviser
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Steven M. Hoffman
    
	
 
    	
Name:
    	
Steven M. Hoffman
    
	
 
    	
Title:
    	
Vice President and Counsel
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
NORTH RIVER INVESTORS (BERMUDA) L.P.
    
	
 
    	
 
    
	
 
    	
By:
    	
Wellington Management Company, LLP,
    
	
 
    	
 
    	
as investment adviser
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Steven M. Hoffman
    
	
 
    	
Name:
    	
Steven M. Hoffman
    
	
 
    	
Title:
    	
Vice President and Counsel
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
NORTH RIVER PARTNERS, L.P.
    
	
 
    	
 
    
	
 
    	
By:
    	
Wellington Management Company, LLP,
    
	
 
    	
 
    	
as investment adviser
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Steven M. Hoffman
    
	
 
    	
Name:
    	
Steven M. Hoffman
    
	
 
    	
Title:
    	
Vice President and Counsel
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
SALTHILL INVESTORS (BERMUDA) L.P.
    
	
 
    	
 
    
	
 
    	
By:
    	
Wellington Management Company, LLP,
    
	
 
    	
 
    	
as investment adviser
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Steven M. Hoffman
    
	
 
    	
Name:
    	
Steven M. Hoffman
    
	
 
    	
Title:
    	
Vice President and Counsel
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SIGNATURE PAGE TO

INVITAE CORPORATION

OMNIBUS APPROVAL AND AMENDMENT

DATED AS OF OCTOBER 7, 2014

 

The undersigned hereby executes and delivers the Omnibus Approval and Amendment (the “Amendment”) to which this additional signature page is attached effective as the Effective Date (as defined in the Amendment), which, together with all counterparts thereto and signature pages of the other parties with respect thereto, shall constitute one and the same document in accordance with the terms of the Amendment.

 

 

	
 
    	
SALTHILL PARTNERS, L.P.
    
	
 
    	
 
    
	
 
    	
By:
    	
Wellington Management Company, LLP,
    
	
 
    	
 
    	
as investment adviser
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Steven M. Hoffman
    
	
 
    	
Name:
    	
Steven M. Hoffman
    
	
 
    	
Title:
    	
Vice President and Counsel
    

 

Note: Below information is only relevant for Purchasers in Final Closing

 

	
 
    	
-
    	
Shares of Series F Preferred Stock Purchased in Final Closing
    
	
 
    	
 
    	
 
    
	
 
    	
-
    	
Aggregate Purchase Price for Final Closing Investment
    

 

[Signature page to Omnibus Approval and Amendment]

 

 

SCHEDULE A

 

“Subsequent Purchasers” are the following persons and entities:

 

	
Purchaser
    	
 
    	
Shares Purchased
    	
 
    	
Purchase Price
    	
 
    
	
BlackRock Global Allocation Fund, Inc.
    	
 
    	
14,195,190
    	
 
    	
$
    	
28,390,380
    	
 
    
	
BlackRock Global Allocation V.I. Fund of BlackRock   Variable Series Funds, Inc.
    	
 
    	
2,896,633
    	
 
    	
$
    	
5,793,266
    	
 
    
	
BlackRock Global Allocation Portfolio of BlackRock   Series Fund, Inc.
    	
 
    	
64,815
    	
 
    	
$
    	
129,630
    	
 
    
	
BlackRock Global Allocation Fund (Australia)
    	
 
    	
247,498
    	
 
    	
$
    	
494,996
    	
 
    
	
MassMutual Select BlackRock Global Allocation Fund
    	
 
    	
167,841
    	
 
    	
$
    	
335,682
    	
 
    
	
JNL/BlackRock Global Allocation Fund of JNL   Series Trust
    	
 
    	
839,273
    	
 
    	
$
    	
1,678,546
    	
 
    
	
BlackRock Global Funds — Global Allocation Fund
    	
 
    	
5,603,429
    	
 
    	
$
    	
11,206,858
    	
 
    
	
BlackRock Global Funds — Global Dynamic Equity   Fund
    	
 
    	
369,458
    	
 
    	
$
    	
738,916
    	
 
    
	
AZL BlackRock Global Allocation Fund, a   Series of Allianz Variable Insurance Products Trust
    	
 
    	
186,439
    	
 
    	
$
    	
372,878
    	
 
    
	
BlackRock Global Allocation Collective Fund
    	
 
    	
429,424
    	
 
    	
$
    	
858,848
    	
 
    
	
667, L.P. (account #1)
    	
 
    	
629,600
    	
 
    	
$
    	
1,259,200
    	
 
    
	
667, L.P. (account #2)
    	
 
    	
447,230
    	
 
    	
$
    	
894,460
    	
 
    
	
Baker Brothers Life Sciences, L.P.
    	
 
    	
8,923,170
    	
 
    	
$
    	
17,846,340
    	
 
    
	
Genesys Ventures II LP
    	
 
    	
500,000
    	
 
    	
$
    	
1,000,000
    	
 
    
	
TOTAL:
    	
 
    	
35,500,000
    	
 
    	
$
    	
71,000,000Exhibit 10.1

 

INDEMNIFICATION AGREEMENT

 

This Indemnification Agreement (the “Agreement”), dated as of             , 2015, between Invitae Corporation, a Delaware corporation (the “Corporation”), and               (“Indemnitee”),

 

W I T N E S S E T H:

 

WHEREAS, Indemnitee is either a member of the board of directors of the Corporation (the “Board of Directors”) or an officer of the Corporation, or both, and in such capacity or capacities, or otherwise as an Agent (as hereinafter defined) of the Corporation, is performing a valuable service for the Corporation; and

 

WHEREAS, the Corporation is aware that competent and experienced persons are increasingly reluctant to serve as directors or officers of corporations or other business entities unless they are protected by comprehensive indemnification and liability insurance, due to increased exposure to litigation costs and risks resulting from their service to such corporations, and because the exposure frequently bears no reasonable relationship to the compensation of such directors and officers; and

 

WHEREAS, the Board of Directors of the Corporation has concluded that, to retain and attract talented and experienced individuals to serve or continue to serve as officers or directors of the Corporation or as an Agent, and to encourage such individuals to take the business risks necessary for the success of the Corporation, it is necessary for the Corporation contractually to indemnify directors, officers and Agents and to assume for itself to the fullest extent permitted by law expenses and damages in connection with claims against such officers, directors and Agents in connection with their service to the Corporation; and

 

WHEREAS, Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”), under which the Corporation is organized, empowers the Corporation to indemnify by agreement its officers, directors, employees and agents, and persons who serve, at the request of the Corporation, as directors, officers, employees or agents of other corporations or enterprises, and expressly provides that the indemnification provided by the DGCL is not exclusive; and

 

WHEREAS, the Corporation desires and has requested the Indemnitee to serve or continue to serve as a director, officer or Agent of the Corporation free from undue concern for claims for damages arising out of or related to such services to the Corporation; and

 

WHEREAS, Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Corporation on the condition that he or she be indemnified as herein provided; and

 

WHEREAS, it is intended that Indemnitee shall be paid promptly by the Corporation all amounts necessary to effectuate in full the indemnity provided herein; and

 

WHEREAS, certain defined terms are set forth in Section 17 below:

 

 

NOW, THEREFORE, in consideration of the premises and the covenants in this Agreement, and of Indemnitee serving or continuing to serve the Corporation as an Agent and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.              Services by Indemnitee.  Indemnitee agrees to serve or continue to serve (a) as a director or an officer of the Corporation, or both, so long as Indemnitee is duly appointed or elected and qualified, and until such time as Indemnitee resigns or fails to stand for election or is removed from Indemnitee’s position in each case in accordance with the applicable provisions of the Certificate of Incorporation and Bylaws of the Corporation, or (b) otherwise as an Agent of the Corporation.  Indemnitee may from time to time also perform other services at the request or for the convenience of, or otherwise benefiting the Corporation or any subsidiary of the Corporation.  Indemnitee may at any time and for any reason resign or be removed from such position (subject to any other contractual obligation or other obligation imposed by operation of law), in which event the Corporation shall have no obligation under this Agreement to continue Indemnitee in any such position.

 

2.                                      Indemnification of Indemnitee.  Subject to the limitations set forth herein and particularly in Section 6 hereof, the Corporation hereby agrees to indemnify Indemnitee as follows:

 

(a)                                 The Corporation shall, with respect to any Proceeding (as hereinafter defined), indemnify Indemnitee to the fullest extent permitted by applicable law or as such law may from time to time be amended (but, in the case of any such amendment, only to the extent such amendment permits the Corporation to provide broader indemnification rights than the law permitted the Corporation to provide before such amendment).  The right to indemnification conferred herein shall be presumed to have been relied upon by Indemnitee in serving or continuing to serve the Corporation as an Agent and shall be enforceable as a contract right.  Without in any way diminishing the scope of the indemnification provided by this Section 2(a), the rights of indemnification of Indemnitee shall include but shall not be limited to those rights hereinafter set forth.

 

(b)                                 The Corporation shall indemnify Indemnitee if Indemnitee is or was a party or is threatened to be made a party to any Proceeding (other than an action by or in the right of the Corporation) by reason of the fact that Indemnitee is or was an Agent of the Corporation, or any subsidiary of the Corporation, or by reason of the fact that Indemnitee is or was serving at the request of the Corporation as an Agent of another corporation, partnership, joint venture, trust or other enterprise, against Expenses (as hereinafter defined) or Liabilities (as hereinafter defined), actually and reasonably incurred by Indemnitee in connection with such Proceeding if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe Indemnitee’s conduct was unlawful.

 

2

 

(c)                                  The Corporation shall indemnify Indemnitee if Indemnitee was or is a party or is threatened to be made a party to any Proceeding by or in the right of the Corporation or any subsidiary of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was an Agent of the Corporation, or any subsidiary of the Corporation, or by reason of the fact that Indemnitee is or was serving at the request of the Corporation as an Agent of another corporation, partnership, joint venture, trust or other enterprise, against Expenses and, to the fullest extent permitted by law, Liabilities if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to the Corporation unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the State of Delaware or such other court shall deem proper.

 

3.                                      Advancement of Expenses.  All reasonable Expenses incurred by or on behalf of Indemnitee (including costs of enforcement of this Agreement) shall be advanced from time to time by the Corporation to Indemnitee within thirty (30) days after the receipt by the Corporation of a written request for an advance of Expenses, whether prior to or after final disposition of a Proceeding (except to the extent that there has been a Final Adverse Determination (as hereinafter defined) that Indemnitee is not entitled to be indemnified for such Expenses), including without limitation any Proceeding brought by or in the right of the Corporation.  The written request for an advancement of any and all Expenses under this paragraph shall contain reasonable detail of the Expenses incurred by Indemnitee.  In the event that such written request shall be accompanied by an affidavit of counsel to Indemnitee to the effect that such counsel has reviewed such Expenses and that such Expenses are reasonable in such counsel’s view, then such expenses shall be deemed reasonable in the absence of clear and convincing evidence to the contrary.  By execution of this Agreement, Indemnitee shall be deemed to have made whatever undertaking as may be required by law at the time of any advancement of Expenses with respect to repayment to the Corporation of such Expenses.  In the event that the Corporation shall breach its obligation to advance Expenses under this Section 3, the parties hereto agree that Indemnitee’s remedies available at law would not be adequate and that Indemnitee would be entitled to specific performance.

 

4.                                      Presumptions and Effect of Certain Proceedings.  Upon making a request for indemnification, Indemnitee shall be presumed to be entitled to indemnification under this Agreement and the Corporation shall have the burden of proof to overcome that presumption in reaching any contrary determination.  The termination of any Proceeding by judgment, order, settlement, arbitration award or conviction, or upon a plea of nolo contendere or its equivalent shall not affect this presumption or, except as determined by a judgment or other final adjudication adverse to Indemnitee, establish a presumption with regard to any factual matter relevant to determining Indemnitee’s rights to indemnification hereunder.  If the person or persons so empowered to make a determination pursuant to Section 5 hereof shall have failed to make the requested determination within the period provided for in Section 5 hereof, a determination that Indemnitee is entitled to indemnification shall be deemed to have been made.

 

3

 

5.                                      Procedure for Determination of Entitlement to Indemnification.

 

(a)                                 Whenever Indemnitee believes that Indemnitee is entitled to indemnification pursuant to this Agreement, Indemnitee shall submit a written request for indemnification to the Corporation.  Any request for indemnification shall include sufficient documentation or information reasonably available to Indemnitee for the determination of entitlement to indemnification.  In any event, Indemnitee shall submit Indemnitee’s claim for indemnification within a reasonable time, not to exceed five (5) years after any judgment, order, settlement, dismissal, arbitration award, conviction, acceptance of a plea of nolo contendere or its equivalent, or final determination, whichever is the later date for which Indemnitee requests indemnification.  The Secretary or other appropriate officer shall, promptly upon receipt of Indemnitee’s request for indemnification, advise the Board of Directors in writing that Indemnitee has made such request.  Determination of Indemnitee’s entitlement to indemnification shall be made not later than sixty (60) days after the Corporation’s receipt of Indemnitee’s written request for such indemnification, provided that any request for indemnification for Liabilities, other than amounts paid in settlement, shall have been made after a determination thereof in a Proceeding.  If it is so determined that the Indemnitee is entitled to indemnification, and Indemnitee has already paid the Liabilities, reimbursement to the Indemnitee shall be made within ten (10) days after such determination; otherwise, the Corporation shall pay the Liabilities on behalf of the Indemnitee if and when the Indemnitee becomes legally obligated to make payment.

 

(b)                                 The Corporation shall be entitled to select the forum in which Indemnitee’s entitlement to indemnification will be heard; provided, however, that if there is a Change in Control of the Corporation, Independent Legal Counsel (as hereinafter defined) shall determine whether Indemnitee is entitled to indemnification.  The forum shall be any one of the following:

 

(i)                                     a majority vote of Disinterested Directors (as hereinafter defined), even though less than a quorum;

 

(ii)                                  by a committee of Disinterested Directors designated by majority vote of Disinterested Directors, even though less than a quorum;

 

(iii)                               Independent Legal Counsel, whose determination shall be made in a written opinion; or

 

(iv)                              the stockholders of the Corporation.

 

6.                                      Specific Limitations on Indemnification.  Notwithstanding anything in this Agreement to the contrary, the Corporation shall not be obligated under this Agreement to make any payment to Indemnitee with respect to any Proceeding (and Indemnitee hereby waives and relinquishes any right under this Agreement, the Certificate of Incorporation, the Bylaws or otherwise to be indemnified and held harmless or to receive any advancement of Expenses):

 

(a)                                 To the extent that payment is actually made to Indemnitee under any insurance policy, or is made to Indemnitee by the Corporation or an affiliate otherwise than pursuant to this Agreement.  Notwithstanding the availability of such insurance, Indemnitee also may claim indemnification from the Corporation pursuant to this Agreement by assigning to the Corporation any claims under such insurance to the extent Indemnitee is paid by the Corporation;

 

4

 

(b)                                 Provided there has been no Change in Control, for Liabilities in connection with Proceedings settled without the Corporation’s consent, which consent, however, shall not be unreasonably withheld;

 

(c)                                  For an accounting of profits made from the purchase or sale by Indemnitee of securities of the Corporation within the meaning of section 16(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or similar provisions of any state statutory or common law;

 

(d)                                 To the extent it would be otherwise prohibited by law, if so established by a judgment or other final adjudication adverse to Indemnitee; or

 

(e)                                  In connection with a Proceeding commenced by Indemnitee (other than a Proceeding commenced by Indemnitee to enforce Indemnitee’s rights under this Agreement) unless the commencement of such Proceeding was authorized by the Board of Directors.

 

7.                                      Fees and Expenses of Independent Legal Counsel.  The Corporation agrees to pay the reasonable fees and expenses of Independent Legal Counsel should such Independent Legal Counsel be retained to make a determination of Indemnitee’s entitlement to indemnification pursuant to Section 5(b) of this Agreement, and to fully indemnify such Independent Legal Counsel against any and all expenses and losses incurred by any of them arising out of or relating to this Agreement or their engagement pursuant hereto.

 

8.                                      Remedies of Indemnitee.

 

(a)                                 In the event that (i) a determination pursuant to Section 5 hereof is made that Indemnitee is not entitled to indemnification, (ii) advances of Expenses are not made pursuant to this Agreement, (iii) payment has not been timely made following a determination of entitlement to indemnification pursuant to this Agreement, or (iv) Indemnitee otherwise seeks enforcement of this Agreement, Indemnitee shall be entitled to a final adjudication in the Court of Chancery of the State of Delaware of the remedy sought.  Alternatively, unless court approval is required by law for the indemnification sought by Indemnitee, Indemnitee at Indemnitee’s option may seek an award in arbitration to be conducted by a single arbitrator pursuant to the commercial arbitration rules of the American Arbitration Association now in effect, which award is to be made within ninety (90) days following the filing of the demand for arbitration.  The Corporation shall not oppose Indemnitee’s right to seek any such adjudication or arbitration award.  In any such proceeding or arbitration Indemnitee shall be presumed to be entitled to indemnification and advancement of Expenses under this Agreement and the Corporation shall have the burden of proof to overcome that presumption.

 

(b)                                 In the event that a determination that Indemnitee is not entitled to indemnification, in whole or in part, has been made pursuant to Section 5 hereof, the decision in the judicial proceeding or arbitration provided in paragraph (a) of this Section 8 shall be made de novo and Indemnitee shall not be prejudiced by reason of a determination that Indemnitee is not entitled to indemnification.

 

5

 

(c)                                  If a determination that Indemnitee is entitled to indemnification has been made pursuant to Section 5 hereof, or is deemed to have been made pursuant to Section 4 hereof or otherwise pursuant to the terms of this Agreement, the Corporation shall be bound by such determination.

 

(d)                                 The Corporation shall be precluded from asserting that the procedures and presumptions of this Agreement are not valid, binding and enforceable.  The Corporation shall stipulate in any such court or before any such arbitrator that the Corporation is bound by all the provisions of this Agreement and is precluded from making any assertion to the contrary.

 

(e)                                  Expenses reasonably incurred by Indemnitee in connection with Indemnitee’s request for indemnification under, seeking enforcement of or to recover damages for breach of this Agreement shall be advanced by the Corporation when and as incurred by Indemnitee irrespective of any Final Adverse Determination that Indemnitee is not entitled to indemnification.

 

9.                                      Contribution.  To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Corporation, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Corporation and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Corporation (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).

 

10.                               Maintenance of Insurance.  The Corporation represents that it presently has in place certain directors’ and officers’ liability insurance policies covering its directors and officers.  Subject only to the provisions within this Section 10, the Corporation agrees that so long as Indemnitee shall have consented to serve or shall continue to serve as a director or officer of the Corporation, or both, or as an Agent of the Corporation, and thereafter so long as Indemnitee shall be subject to any possible Proceeding (such periods being hereinafter sometimes referred to as the “Indemnification Period”), the Corporation will use all reasonable efforts to maintain in effect for the benefit of Indemnitee one or more valid, binding and enforceable policies of directors’ and officers’ liability insurance from established and reputable insurers, providing, in all respects, coverage both in scope and amount which is no less favorable than that presently provided or, following the Corporation’s initial public offering, than that provided as of the time of such initial public offering.  Notwithstanding the foregoing, the Corporation shall not be required to maintain said policies of directors’ and officers’ liability insurance during any time period if during such period such insurance is not reasonably available or if it is determined in good faith by the then directors of the Corporation either that:

 

(i)                                     The premium cost of maintaining such insurance is substantially disproportionate to the amount of coverage provided thereunder; or

 

6

 

(ii)                                  The protection provided by such insurance is so limited by exclusions, deductions or otherwise that there is insufficient benefit to warrant the cost of maintaining such insurance.

 

Anything in this Agreement to the contrary notwithstanding, to the extent that and for so long as the Corporation shall choose to continue to maintain any policies of directors’ and officers’ liability insurance during the Indemnification Period, the Corporation shall maintain similar and equivalent insurance for the benefit of Indemnitee during the Indemnification Period (unless such insurance shall be less favorable to Indemnitee than the Corporation’s existing policies).

 

11.                               Modification, Waiver, Termination and Cancellation.  No supplement, modification, termination, cancellation or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar), nor shall such waiver constitute a continuing waiver.

 

12.                               Subrogation.  In the event of payment under this Agreement, the Corporation shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable the Corporation effectively to bring suit to enforce such rights.

 

13.                               Notice by Indemnitee and Defense of Claim.  Indemnitee shall promptly notify the Corporation in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any matter, whether civil, criminal, administrative or investigative that may result in the right to indemnification or the advancement of Expenses, but the omission so to notify the Corporation will not relieve it from any liability that it may have to Indemnitee if such omission does not prejudice the Corporation’s rights.  If such omission does prejudice the Corporation’s rights, the Corporation will be relieved from liability only to the extent of such prejudice.  Notwithstanding the foregoing, such omission will not relieve the Corporation from any liability that it may have to Indemnitee otherwise than under this Agreement.  With respect to any Proceeding as to which Indemnitee notifies the Corporation of the commencement thereof:

 

(a)                                 The Corporation will be entitled to participate therein at its own expense; and

 

(b)                                 The Corporation jointly with any other indemnifying party similarly notified will be entitled to assume the defense thereof, with counsel reasonably satisfactory to Indemnitee; provided, however, that the Corporation shall not be entitled to assume the defense of any Proceeding if there has been a Change in Control or if Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Corporation and Indemnitee with respect to such Proceeding.  After notice from the Corporation to Indemnitee of its election to assume the defense thereof, the Corporation will not be liable to Indemnitee under this Agreement for any Expenses subsequently incurred by Indemnitee in connection with the defense thereof, other than reasonable costs of investigation or as otherwise provided below.  Indemnitee shall have the right to employ Indemnitee’s own counsel in such Proceeding, but the fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense of Indemnitee unless:

 

7

 

(i)                                     the employment of counsel by Indemnitee has been authorized by the Corporation;

 

(ii)                                  Indemnitee shall have reasonably concluded that counsel engaged by the Corporation may not adequately represent Indemnitee due to, among other things, actual or potential differing interests; or

 

(iii)                               the Corporation shall not in fact have employed counsel to assume the defense in such Proceeding or shall not in fact have assumed such defense and be acting in connection therewith with reasonable diligence; in each of which cases the fees and expenses of such counsel shall be at the expense of the Corporation.

 

(c)                                  The Corporation shall not settle any Proceeding in any manner that would impose any penalty or limitation on Indemnitee without Indemnitee’s written consent; provided, however, that Indemnitee will not unreasonably withhold his or her consent to any proposed settlement.

 

14.                               Notices.  All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:

 

(a)                                 If to Indemnitee, to the address set forth below Indemnitee’s signature on the signature page hereof.

 

(b)                                 If to the Corporation, to:

Invitae Corporation

458 Brannan Street

San Francisco, CA 94107

 

or to such other address as may have been furnished to Indemnitee by the Corporation or to the Corporation by Indemnitee, as the case may be.

 

15.                               Nonexclusivity.  The rights of Indemnitee hereunder shall not be deemed exclusive of any other rights to which Indemnitee may be entitled under applicable law, the Corporation’s Certificate of Incorporation or Bylaws, or any agreements, vote of stockholders, resolution of the Board of Directors or otherwise, and to the extent that during the Indemnification Period the rights of the then existing directors and officers are more favorable to such directors or officers than the rights currently provided to Indemnitee thereunder or under this Agreement, Indemnitee shall be entitled to the full benefits of such more favorable rights.

 

8

 

16.                               Indemnification and Advancement Rights Primary.  The Corporation hereby acknowledges that Indemnitee has or may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more parties other than the Corporation or an affiliate of the Corporation (collectively, the “Secondary Indemnitors”).  The Corporation hereby acknowledges and the Corporation and Indemnitee hereby agree: (i) that the Corporation is the indemnitor of first resort; i.e., its obligations to Indemnitee are primary and any obligation of the Secondary Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary; (ii) that the Corporation shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the Certificate of Incorporation and/or Bylaws of the Corporation (or any other agreement between the Corporation and Indemnitee), without regard to any rights Indemnitee may have against the Secondary Indemnitors; and (iii) that the Corporation irrevocably waives, relinquishes and releases the Secondary Indemnitors from any and all claims against the Secondary Indemnitors that the Corporation may have for contribution, subrogation or any other recovery of any kind in respect thereof.  The Corporation further agrees that no advancement or payment by the Secondary Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Corporation shall affect the foregoing and the Secondary Indemnitors shall have a right of contribution and/or subrogation to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Corporation.  The Corporation and Indemnitee agree that the Secondary Indemnitors are express third party beneficiaries of the terms of this provision.

 

17.                               Certain Definitions.

 

(a)                                 “Agent” shall mean any person who is or was, or who has consented to serve as, a director, officer, employee, agent, fiduciary, joint venturer, partner, manager or other official of the Corporation or a subsidiary or an affiliate of the Corporation, or any other entity (including without limitation, an employee benefit plan), in each case either at the request of, for the convenience of, or otherwise to benefit the Corporation or a subsidiary of the Corporation.  Any person who is or was serving as a director, officer, employee or agent of a subsidiary of the Corporation shall be deemed to be serving, or have served, at the request of the Corporation.

 

(b)                                 “Change in Control” shall mean the occurrence, after the Corporation’s initial public offering, of any of the following:

 

(i)                                     Both (A) any “person” (as defined below) is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Corporation representing at least twenty percent (20%) of the total voting power represented by the Corporation’s then outstanding voting securities and (B) the beneficial ownership by such person of securities representing such percentage is not approved by a majority of the “Continuing Directors” (as defined below);

 

(ii)                                  Any “person” is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Corporation representing at least fifty percent (50%) of the total voting power represented by the Corporation’s then outstanding voting securities;

 

9

 

(iii)                               A change in the composition of the Board of Directors occurs, as a result of which fewer than two-thirds of the incumbent directors are directors (the “Continuing Directors”) who either (A) had been directors of the Corporation on the “look-back date” (as defined below) (the “Original Directors”) or (B) were elected, or nominated for election, to the Board of Directors with the affirmative votes of at least a majority in the aggregate of the Original Directors who were still in office at the time of the election or nomination and directors whose election or nomination was previously so approved;

 

(iv)                              The stockholders of the Corporation approve a merger or consolidation of the Corporation with any other corporation, if such merger or consolidation would result in the voting securities of the Corporation outstanding immediately prior thereto representing (either by remaining outstanding or by being converted into voting securities of the surviving entity) 50% or less of the total voting power represented by the voting securities of the Corporation or such surviving entity outstanding immediately after such merger or consolidation; or

 

(v)                                 The stockholders of the Corporation approve (A) a plan of complete liquidation of the Corporation or (B) an agreement for the sale or disposition by the Corporation of all or substantially all of the Corporation’s assets.

 

For purposes of Subsections (i) and (ii) above, the term “person” shall have the same meaning as when used in sections 13(d) and 14(d) of the Exchange Act, but shall exclude (x) a trustee or other fiduciary holding securities under an employee benefit plan of the Corporation or of a parent or subsidiary of the Corporation or (y) a corporation owned directly or indirectly by the stockholders of the Corporation in substantially the same proportions as their ownership of the common stock of the Corporation.

 

For purposes of Subsection (iii) above, the term “look-back date” shall mean the later of (x) the date first written above in the preamble to this Agreement or (y) the date 24 months prior to the date of the event that may constitute a “Change in Control.”

 

Any other provision of this Section 17(b) notwithstanding, the term “Change in Control” shall not include a transaction, if undertaken at the election of the Corporation, the result of which is to sell all or substantially all of the assets of the Corporation to another corporation (the “surviving corporation”); provided that the surviving corporation is owned directly or indirectly by the stockholders of the Corporation immediately following such transaction in substantially the same proportions as their ownership of the Corporation’s common stock immediately preceding such transaction; and provided, further, that the surviving corporation expressly assumes this Agreement.

 

(c)                                  “Disinterested Director” shall mean a director of the Corporation who is not or was not a party to the Proceeding in respect of which indemnification is being sought by Indemnitee.

 

10

 

(d)                                 “Expenses” shall include all direct and indirect costs (including, without limitation, attorneys’ fees, retainers, court costs, transcripts, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, all other disbursements or out-of-pocket expenses and reasonable compensation for time spent by Indemnitee for which Indemnitee is otherwise not compensated by the Corporation or any third party) actually and reasonably incurred in connection with either the investigation, defense, settlement or appeal of a Proceeding or establishing or enforcing a right to indemnification under this Agreement, applicable law or otherwise; provided, however, that “Expenses” shall not include any Liabilities.

 

(e)                                  “Final Adverse Determination” shall mean that a determination that Indemnitee is not entitled to indemnification shall have been made pursuant to Section 5 hereof and either (1) a final adjudication in the courts of the State of Delaware from which there is no further right of appeal or decision of an arbitrator pursuant to Section 8(a) hereof shall have denied Indemnitee’s right to indemnification hereunder, or (2) Indemnitee shall have failed to file a complaint in a Delaware court or seek an arbitrator’s award pursuant to Section 8(a) for a period of one hundred twenty (120) days after the determination made pursuant to Section 5 hereof.

 

(f)                                   “Independent Legal Counsel” shall mean a law firm or a member of a firm selected by the Corporation and approved by Indemnitee (which approval shall not be unreasonably withheld) or, if there has been a Change in Control, selected by Indemnitee and approved by the Corporation (which approval shall not be unreasonably withheld), that neither is presently nor in the past five (5) years has been retained to represent:  (i) the Corporation or any of its subsidiaries or affiliates, or Indemnitee or any corporation of which Indemnitee was or is a director, officer, employee or agent, or any subsidiary or affiliate of such a corporation, in any material matter, or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.  Notwithstanding the foregoing, the term “Independent Legal Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Corporation or Indemnitee in an action to determine Indemnitee’s right to indemnification under this Agreement.

 

(g)                                  “Liabilities” shall mean liabilities of any type whatsoever including, but not limited to, any judgments, fines, Employee Retirement Income Security Act excise taxes and penalties, penalties and amounts paid in settlement (including all interest assessments and other charges paid or payable in connection with or in respect of such judgments, fines, penalties or amounts paid in settlement) of any Proceeding.

 

(h)                                 “Proceeding” shall mean any threatened, pending or completed action, claim, suit, arbitration, alternate dispute resolution mechanism, investigation, administrative hearing or any other proceeding whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party, as a witness or otherwise, that is associated with Indemnitee’s being an Agent of the Corporation.

 

18.                               Binding Effect; Duration and Scope of Agreement.  This Agreement shall be binding upon the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Corporation), spouses, heirs and personal and legal representatives.  This Agreement shall be deemed to be effective as of the commencement date of the Indemnitee’s service as an officer or director of the Corporation and shall continue in effect during the Indemnification Period, regardless of whether Indemnitee continues to serve as an Agent.

 

11

 

19.                               Severability.  If any provision or provisions of this Agreement (or any portion thereof) shall be held to be invalid, illegal or unenforceable for any reason whatsoever:

 

(a)                                 the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby; and

 

(b)                                 to the fullest extent legally possible, the provisions of this Agreement shall be construed so as to give effect to the intent of any provision held invalid, illegal or unenforceable.

 

20.                               Governing Law.  This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware, as applied to contracts between Delaware residents entered into and to be performed entirely within the State of Delaware, without regard to conflict of laws rules.

 

21.                               Consent to Jurisdiction.  Except with respect to any arbitration commenced by Indemnitee pursuant to Section 8 of this Agreement, the Corporation and Indemnitee each irrevocably consent to the jurisdiction of the courts of the State of Delaware for all purposes in connection with any action or proceeding that arises out of or relates to this Agreement and agree that any action instituted under this Agreement shall be brought only in the state courts of the State of Delaware.

 

22.                               Entire Agreement.  This Agreement represents the entire agreement between the parties hereto, and there are no other agreements, contracts or understandings between the parties hereto with respect to the subject matter of this Agreement, except as specifically referred to herein or as provided in Section 15 hereof.

 

23.                               Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.

 

[* * *]

 

12

 

IN WITNESS WHEREOF, the Corporation has caused this Agreement to be executed by a duly authorized officer and Indemnitee has executed this Agreement as of the date first above written.

 

	
 
    	
INVITAE   CORPORATION,
    
	
 
    	
a Delaware corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By
    	
 
    
	
 
    	
Its
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
INDEMNITEE
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Address:
    
	
 
    	
 
    
	
 
    	
 
    

 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]